Content
All Posts > Content under Healthcare
5 Drug Stocks Well Poised To Beat Q2 Earnings Estimates
Article By:
Zacks Investment Research
Read
Thursday, July 13, 2017 4:58 PM EDT
The pharma/biotech sector has picked up this year after being battered by the drug pricing controversy in 2016. The first half has been pretty strong for companies in the space.
Better Dividend Aristocrat: Johnson & Johnson Or Medtronic?
Article By:
SureDividend
Read
Thursday, July 13, 2017 2:02 PM EDT
There is little doubt that both Medtronic and J&J are high-quality businesses. Investors will likely do well with either stock.
5 Stocks With Recent Price Strength To Enhance Your Returns
Article By:
Zacks Investment Research
Read
Thursday, July 13, 2017 1:07 PM EDT
Every investor wishes to have a magical portfolio of stocks with a one way ticket to success. But this is easier said than done. And when the market is as volatile as it is now, things may take a turn for the worse any moment.
Intro Guide To The Fidelity Select Medical Equipment & Systems Fund (FSMEX)
Article By:
Zacks Investment Research
Read
Thursday, July 13, 2017 9:48 AM EDT
FSMEX’s performance, as of the last filing, when compared to funds in its category was in the top 24% in 1 year, top 1% over the past 3 years, and in the 4% over the past 5 years.
In this article: FSMEX
OpGen Announces Pricing Of $10.0 Million Public Offering
Article By:
NASDAQ GlobeNewswire
Read
Thursday, July 13, 2017 9:18 AM EDT
OpGen, Inc. announces the pricing of a public offering of an aggregate of 25,000,000 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one share of common stock.
In this article: OPGN
VBI Vaccines: Hidden Vaccine Gem
Article By:
Stone Fox Capital
Read
Thursday, July 13, 2017 9:05 AM EDT
VBI Vaccines is starting Phase III trials for a vaccine approved in multiple countries while the stock trades near the recent lows providing a large catalyst for the stock.
Should You Bet On The Smart Drug Market?
Article By:
Maithya Kitonyi
Read
Thursday, July 13, 2017 5:56 AM EDT
There seems to be an unquenchable desire in the corporate sector as people continue their pursuit of becoming "Limitless-like Einsteins" by taking nootropics. This has driven growth projection for the smart drug market to about 20% CAGR through 2021.
Abeona Therapeutics - Chart Of The Day
Article By:
Jim Van Meerten
Read
Wednesday, July 12, 2017 5:53 PM EDT
Since the Trend Spotter signaled a buy on 6/2 the stock gained 50.84%.
In this article: ABEO
Three Large Cap Pharma Stocks To Buy Now
Article By:
Zacks Investment Research
Read
Wednesday, July 12, 2017 5:20 AM EDT
While investors might think that the uncertainty of health care reform would bring volatility into the sector, we’ve actually seen healthcare stocks have a pretty decent year so far. The overall “Medical” sector is up about 11.9% year-to-date.
Small Cap Rare Disease Biotechs Jump After Peer Amicus Gets FDA Nod
ImmunoGen
Article By:
Tim Knight
Read
Tuesday, July 11, 2017 4:06 PM EDT
So far, IMGN it’s giving me weak results.
In this article: IMGN
Immune Pharma To Unlock Value And Create Two Separate Pure Play Companies; Cytovia, Immune
Article By:
Ari Zoldan
Read
Tuesday, July 11, 2017 3:13 PM EDT
Immune expects that the focus of Cytovia will be the European market for the drug, which has an addressable market of $175 million, while Pint will focus on the Latin America market with an addressable market of $100 million.
MyoKardia Brings Hope To Hypertrophic Cardiomyopathy Patients
Article By:
Scott Matusow
Read
Tuesday, July 11, 2017 10:44 AM EDT
Obstructive Hypertrophic Cardiomyopathy affects roughly 1 out of 500 persons in the U.S, and globally. MyoKardia based on my research has a good chance to successfully treat this highly underserved and unmet need patient population.
Bond Selloff Returns As EM Fears Rise; Oil Slides; BOJ Does Not Intervene
Article By:
Tyler Durden
Read
Tuesday, July 11, 2017 7:26 AM EDT
U.S. index futures point slightly lower open. Asian shares rose while stocks in Europe fell as energy producers got caught in a downdraft in oil prices and reversed an earlier gain after Goldman unexpectedly warned that WTI could slide below $40.